change
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are wrong. See link
https://itunes.apple.com/us/app/adblock-for-ios-must-have/id537774578?mt=8
TA analysis shows OVERBOUGHT territory.
You are wrong. Try AdBlock or similar apps. It is easy.
Short Volume
Date|Symbol|ShortVolume|ShortExemptVolume|TotalVolume|Market
20130911|F|4013695|0|10720894|Q
http://regsho.finra.org/FNSQshvol20130911.txt
Did you hear about Ad(s)Block(er) for Android, iOS, IE, Mozilla, Opera etc.? You can block unwanted ads. It is great for users but not good for advertising.
I have posted above mentioned text yesterday. Who erased, who expurgated my post yesterday? This is not democracy.
Facebook options also traded heavily on Wednesday.
A total of 317,000 calls and 131,000 puts in Facebook changed hands on Wednesday, above its recent combined daily average of 355,000 contracts, according to options analytics firm Trade Alert.
The weekly $45 strike calls expiring this Friday as well as the September $44 and October $45 strike calls are among the busiest options.
"But one play in the options market appears to be making a 'cheap' bet that the recent run higher is overdone," said WhatsTrading.com options strategist Frederic Ruffy.
The top trade on Facebook on Wednesday was a 10,250-lot of September $39 strike puts, which were bought for 7 cents per contract as a new position. The contract, which is out-of-the-money, expires at the end of next week and would be profitable if shares fall below $38.93, Ruffy said.
Bravo, Bulls.
Bought $43,16. My PT is $53.16
FB will be back below $40 soon.
VP STRECH Sells 31.574 of FACEBOOK INC.
http://www.sec.gov/Archives/edgar/data/1326801/000120919113043751/xslF345/doc4.xml
The Biggest Insiders Sales From The Last Week:
MSFT - $162 milion
GOOG - $72 milion
Short Volume 20130909
Date|Symbol|ShortVolume|ShortExemptVolume|TotalVolume|Market
20130909|FB|14413836|4824|30841354|Q
http://regsho.finra.org/FNSQshvol20130909.txt
A Bubble Stock That Keeps Getting Bubblier.
I am not sure.
Some of my friends canceled their FB account within last months. I have not and dont want FB account.
Do not waste your time with FB. Go to your friends and have a good time! It is much better.
Strong Sell Now! FB Is Strongly Overbought!
See Technical Indicators And Short Volume.
Date|Symbol|ShortVolume|ShortExemptVolume|TotalVolume|Market
20130906|FB|23495357|8600|55265566|
http://regsho.finra.org/regsho-Index.html
Aradigm can start Phase 3 trials very soon.
New SEC Form 3.
http://www.sec.gov/Archives/edgar/data/1013238/000118143113047434/xslF345/rrd389497.xml
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: June 2014
Last updated: July 10, 2013
They updated data 2 days after my post 07/08/2013 :)
TIME TO ACCUMULATE ARDM BEFORE START OF PHASE III Pulmaquin® CLINICAL TRIALS.
$ARDM IS 10+ BAGGER STOCK.
Pulmaquin is ready to begin Phase 3 clinical trials. Aradigm has been granted orphan drug designation for liposomal ciprofloxacin for cystic fibrosis in the U.S. and the E.U., and for the combination of liposomal ciprofloxacin and free ciprofloxacin for BE in the U.S. Aradigm's inhaled ciprofloxacin has been also successfully tested in animal models of the bioterrorism infections inhalational tularemia, pneumonic plague and Q-fever.
UP TO $90 MILLION FOR ARDM
The parties have agreed to advance Aradigm's proprietary inhaled ciprofloxacin formulations into Phase III clinical trials in BE.
•Grifols will be responsible for all development and clinical expenses up to a maximum of $65 million for the BE indication.
•Aradigm is entitled to receive cash payments of up to $25 million upon achievement of development milestones.
http://investor.aradigm.com/releasedetail.cfm?releaseid=766164
AMAZON IS ONE OF THE WORST OVERVALUED STOCKS OUT THERE
AMAZON HAS NO FREE CASH FLOW; STOCK WILL HAVE UGLY END.
http://video.cnbc.com/gallery/?video=3000187194&play=1
5 Significant Increases In Short Interest
includes: AMZN, DECK, INTC, TSLA, ZNGA
http://seekingalpha.com/article/1628192-5-significant-increases-in-short-interest?source=google_news
Zacks Rank: #5 STRONG SELL
Short-Term: 1-3 Months
http://www.zacks.com/stock/quote/AMZN?q=AMZN
Aradigm Awarded NIH Grant to Investigate New Methods of Diagnoses of Aspirations of Gastrointestinal Contents into the Respiratory Tract with Scientists at UC San Francisco
http://investor.aradigm.com/releasedetail.cfm?releaseid=783377
Aradigm Awarded NIH Grant
http://investor.aradigm.com/releasedetail.cfm?ReleaseID=781968
The Party on Wall Street is OVER! Be carefull!
See http://www.shadowstats.com/
OVax Estimated Study Completion Date: September 2013
http://ww2.cancercenter.com/press-center/press-releases/2008/05/ovarian-cancer-vaccine-clinical-trial-beginsat-cancer-treatment-centers-of-america/
http://clinicaltrials.gov/ct2/show/NCT00660101?term=avax&rank=3
Royalty payments 12.5% or 20% for ARDM.
Payments
Grifols will make development milestone payments of up to $25 million (with an initial payment of $5 million for initiation of the first Phase 3 clinical trial). On a country-by-country basis, Grifols will make royalty payments on net sales at a rate of either 12.5% or 20% (depending on the amount of global net sales every year) for so long as there is patent coverage or orphan drug designation (or, if longer, a period of 10 years), except that payments will be reduced by half with respect to a given country in the event that an inhaled liquid liposomal product containing ciprofloxacin is approved in the same market for the same indication.
http://www.sec.gov/Archives/edgar/data/1013238/000119312513255019/d548439dprem14a.htm
Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin™
http://investor.aradigm.com/releasedetail.cfm?releaseid=766164
Why should investors buy ARDM?
Cystic fibrosis is a $4.0 billion market.
Cystic fibrosis is a life-threatening genetic disease that causes thick, sticky mucus to form in the lungs, pancreas and other organs. In the lungs, the mucus tends to block the airways, causing lung damage and making these patients highly susceptible to lung infections. According to the Cystic Fibrosis Foundation (CFF), CF affects roughly 30,000 children and adults in the United States (about 55 percent of the patients in the CFF Patient Registry are children), and roughly 70,000 children and adults worldwide. According to the American Lung Association, the direct medical care costs for an individual with CF are currently estimated to be in excess of $40,000 per year. The Company was granted orphan drug designation in the US and EU for the management of CF with inhaled liposomal ciprofloxacin.
CFI/DRCFI for the Treatment of Bronchiectasis.
Approximately 110,000 people suffer from non-cystic fibrosis bronchiectasis (BE) in the US and approximately 25-30% are chronically infected with Pseudomonas aeruginosa (PA). There are no drugs approved for treating BE or the infections associated with BE. Hence, BE represents a significant unmet medical need. Historically, inhaled antibiotics have failed in development for BE patients due to the extreme sensitivity of patients’ lungs, which are even more delicate than in CF
patient’s lungs. Trial data indicates that CFI/DRCFI safely delivers ciprofloxacin to a patient’s lungs without causing the cough, wheezing and bronchoconstriction reactions typical in this population from inhaled antibiotics like TOBI. The significant anti-infective activity of ARD-3100/3150, along with minimal side effects, should reduce pulmonary exacerbations (mostly due to infections), hospital visits, and the need for chronic systemic antibiotics, which lead to toxicity and bacterial resistance.
Liposomal Ciprofloxacin for Inhalation has Unrecognized Potential.
Aradigm is developing a potential best-in-class inhaled antibiotic – a liposomal formulation of ciprofloxacin for inhalation (CFI, ARD-3100) and a secondgeneration formulation, dual release CFI (DRCFI, ARD-3150) to treat bacterial infections in the lungs associated with cystic fibrosis (CF) and bronchiectasis (BE). The Uniqe liposomal formulation improves the pharmacokinetic profile to once daily (QD) versus BID and TID for TOBI (tobramycin) and Cayston (aztreonam). More importantly, the liposomal formulation reduces adverse lung reactions such as bronchospasm that have historically handicapped the development of inhaled antibiotics outside of CF.
Pulmaquin has been tested extensively in preclinical tests, as well as in the ORBIT-2 Phase 2b bronchiectasis study in which outstanding antimicrobial activity coupled with good safety and tolerability was found, and, most importantly, the positive impact on prevention of exacerbations compared to placebo was also observed. Pulmaquin is ready to begin Phase 3 clinical trials. Aradigm has been granted orphan drug designation for liposomal ciprofloxacin for cystic fibrosis in the U.S. and the E.U., and for the combination of liposomal ciprofloxacin and free ciprofloxacin for BE in the U.S. Aradigm's inhaled ciprofloxacin has been also successfully tested in animal models of the bioterrorism infections inhalational tularemia, pneumonic plague and Q-fever.
I do not believe investors have recognized the unique attributes of ARD-3100/3150(CFI/DRCFI) and the implications for utility outside of CF.
Cystic fibrosis is a $4.0 billion market.
The next 10-bagger stock in your portfolio.
Start up of clinical Phase III study with Pulmaquin and Lipoquin™ in BE is comming.
http://investor.aradigm.com/releasedetail.cfm?releaseid=766164
$41.4 million to the ARDM; NEW FORM-8 K
On May 20, 2013, Aradigm Corporation, a California corporation (the “Company”), Grifols, S.A., (“Grifols”) and certain other investors (the “Investors”) entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”), pursuant to which the Company agreed, subject to the terms and conditions set forth in the Stock Purchase Agreement, to issue and sell a total of 209,774,558 shares of the Company’s common stock (“Common Stock”), to Grifols and an additional 124,193,546 shares of Common Stock to the Investors, for a total sale of 333,968,104 shares of Common Stock (the “Company Stock Sale”), for a purchase price of $0.124 per share. The aggregate gross consideration payable to the Company in the Company Stock Sale is approximately $41.4 million.
http://www.sec.gov/Archives/edgar/data/1013238/000119312513235581/d542946d8k.htm
Aradigm (ARDM) rated Buy with price target $1 by Ladenburg Thalmann. Posted Mar 28, 2013.
http://www.aradigm.com/products_pipeline.html
http://clinicaltrials.gov/ct2/results?term=aradigm
http://investor.aradigm.com/releasedetail.cfm?ReleaseID=766164
My price target is $1.50 in 2014-2015 after last news.
Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin™
Spanish drugmaker Grifols said on Tuesday it has signed an exclusive contract to license U.S. Aradigm Corporation's Pulmaquin compound and may take a stake in the California-based firm.
The parties have agreed to advance Aradigm’s proprietary inhaled ciprofloxacin formulations into Phase III clinical trials in BE.
Grifols will be responsible for all development and clinical expenses up to a maximum of $65 million for the BE indication.
Aradigm is entitled to receive cash payments of up to $25 million upon achievement of development milestones.
Grifols is responsible for all commercialization activities and will pay Aradigm tiered royalties on worldwide sales of products utilizing Aradigm’s proprietary inhaled ciprofloxacin formulations.
Grifols will be granted an option to license Aradigm’s AERx®pulmonary drug delivery platform for use with another molecule.
In conjunction with the licensing agreement, Grifols will (upon receipt of Aradigm shareholders’ approval) acquire 35% of Aradigm’s common stock on a fully diluted basis at a price per share of $0.124 for a total investment of approximately $26 million.
Existing Aradigm shareholders, including Tavistock Life Sciences Company and accounts managed by First Eagle Investment Management, LLC, and new investors Great Point Partners, LLC will co-invest in the stock purchase transaction and purchase an additional approximately $15.4 million in Aradigm common stock.
The transaction is subject to certain closing conditions and is expected to close in the second half of 2013. At that point, Grifols will be entitled to designate two directors to serve on the Aradigm Board of Directors.
“Pulmaquin will complement Grifols existing Prolastin-C business. There is significant overlap between Bronchiectasis and Alpha1 physicians and patients,“ said Ramon Riera, President Global Commercial. When launched, Grifols will leverage its existing Pulmonary sales team to commercialize Pulmaquin.
“Grifols is a great fit for us with their global reach of respiratory physicians treating a number of conditions that could benefit from Pulmaquin.” said Igor Gonda, President and CEO, Aradigm Corporation.
http://www.fortmilltimes.com/2013/05/21/2704485/grifols-sa-and-aradigm-corporation.html
Aradigm will unveil partnering soon.
Phase III starts in June 2012.
http://clinicaltrials.gov/ct2/show/NCT01515007?term=aradigm&rank=3
Yes. The best chance for success!
The market for Aradigm Corporation (OTC:ARDM) Phase 2b drug candidate liposomal ciprofloxacin exceeds $4 billion worldwide based on the American Lung Association‘s estimate that the annual medical costs for an individual with CF exceeds $40,000 per year.
Aradigm’s president and CEO Igor Gonda stated that “our partnering discussions and interactions with FDA will now intensify with the goal to work together to make this promising therapy available for this underserved orphan patient population.”
Aradigm will start Phase III of the Pulmaquin (TM) soon.
See link:
http://clinicaltrials.gov/ct2/show/NCT01515007?term=aradigm&rank=3
Aradigm Corporation (OTCBB:ARDM) (" Aradigm " or the "Company")
07.12.2011 announced that the United States Patent and Trademark Office has issued an important patent (U.S. Patent No. 8,071,127) regarding formulations of inhaled liposomal and free ciprofloxacin including its lead preparation, Pulmaquin(TM) (Dual Release Ciprofloxacin for Inhalation, DRCFI, ARD-3150). The Company expects that the patent will provide exclusivity for Pulmaquin until October 22, 2027.
Do you have next 10-bagger stock in your portfolio?
AVAX Continues Slowly Up!
Four Clinical Trials Last Updated December 1-6, 2011!!!
See link: http://clinicaltrials.gov/ct2/results?term=avax
ARDM should go up due Insmed (ARIKACE)...
Shares of Insmed (NASDAQ: INSM) are seeing much strength on Friday after the company announced that the hold on its ARIKACE drug has been lifted by the FDA . Shares were halted before the announcement.
The U.S. Food and Drug Administration lifted the clinical hold previously placed on ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria lung disease. Insmed will continue to engage in discussions with FDA regarding the clinical hold placed on ARIKACE in Cystic Fibrosis patients with Pseudomonas lung infections.
The FDA previously requested that Insmed conduct a phase 2 clinical trial of ARIKACE in adult patients with NTM to provide proof-of-concept efficacy and safety data before proceeding with a phase 3 clinical trial.
Insmed also announced that it will move ahead with the 9-month dog inhalation toxicity study of ARIKACE as previously requested by FDA to determine if the findings of the rat inhalation carcinogenicity study are observed in a non-rodent model. Currently, shares of Insmed are trading about 22% higher in the pre-market session at $4.65 .